Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists
Mariangela Gaudio(Humanitas University), Alberto Zambelli, C. Benvenuti, Rita De Sanctis(Humanitas University), Daniela Bernardi(Humanitas University), Riccardo Gerosa(Humanitas University), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Saltalamacchia, Jacopo Canzian(Humanitas University), Giulia Vatteroni(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Gianpiero Rizzo(Policlinico San Matteo Fondazione)
Cited by 2
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532